Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2025

Genmab — Maj 2025

Planlagt Fastgjort Låst Flyttet Genmab
308 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #142

    GSK has also stopped development of their anti-TIGIT antibody https://www.fiercebiotech.com/biotech/gsk-axes-tigit-drug-midphase-survival-data-disappoint-promoting-partner-iteos-cut-costs

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #143

      Acasunlimab + PD-1 Blockade: Combining Forces to Boost Anti-Tumor Immunotherapy https://www.youtube.com/watch?v=qcUcA1epnWA

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #144

        wouldn't it be fun if JNJ would reconsider the hexabody-CD38 option on the back on this CMS draft guidance lol

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #145

          finally found a Genmab A/S Q1 2025 Earnings Call Transcript -that is not behind a paywall - https://www.marketbeat.com/earnings/reports/2025-5-8-genmab-as-stock/

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #146

            you have to use your imagination a bit to get trough the spelling mistakes...

            1 Reply Last reply
            0
            • blackadderB Offline
              blackadderB Offline
              blackadder
              wrote on sidst redigeret af
              #147

              https://web.quartr.com/link/companies/5475/events/315198/transcript?targetTime=0.0

              1 Reply Last reply
              0
              • blackadderB Offline
                blackadderB Offline
                blackadder
                wrote on sidst redigeret af
                #148

                Jeg bruger denne som en app til min iPhone, der er live streaming og transskription lavet af live streaming, sikkert lavet med et eller andet whisperprogram.

                1 Reply Last reply
                0
                • blackadderB Offline
                  blackadderB Offline
                  blackadder
                  wrote on sidst redigeret af
                  #149

                  Det er som at gå at høre podcast for investorer.

                  1 Reply Last reply
                  0
                  • blackadderB Offline
                    blackadderB Offline
                    blackadder
                    wrote on sidst redigeret af
                    #150

                    Undskyld jeg spammer chatten. Linket er et direkte link fra mobilappen til Genmab Q1 2025 live event med transskription. Appen er helt gratis at bruge og guf for investornørder

                    1 Reply Last reply
                    0
                    • L Offline
                      L Offline
                      lahn1
                      wrote on sidst redigeret af
                      #151

                      Fin app ! 🙂

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #152

                        C25-regnskaber, 1. kvartal 2025: Karakterbogen https://proinvestor.com/boards/126363

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #153

                          Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress https://ir.genmab.com/news-releases/news-release-details/genmab-present-new-and-updated-results-its-robust-epcoritamab

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #154

                            Investeringspodcasten 274: Status på de danske aktier https://proinvestor.com/boards/126364

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #155

                              Genmab: 14.33

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #156

                                EHA 25 embargoed until Thursday, June 12

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #157

                                  actually, we can see them now already

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #158

                                    maybe i should post the link for the more
                                    lazy people https://library.ehaweb.org/eha/#!*search=epcoritamab*browseby=8*listing=0*sortby=1

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #159

                                      EHA25 - EPCORE NHL-5 - Fixed-duration epcor + pola-R-CHP with follow-up of 16.1 mos in pts with newly diagnosed : ORR was 100% with 97% achieving a CR

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #160

                                        EHA25 - EPCORE NHL-2 -Epcor + R-ICE demonstrated high CR rates in pts with R/R DLBCL eligible for ASCT, most of whom were high risk, having progressed <12 mo of 1L tx. ORR was 87%; 20 pts (65%) had a CR and 7 (23%) a partial response (PR

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #161

                                          Til sammenligning til EPCORE NHL-2: Background:
                                          First-line (1L) standard of care (SOC) for diffuse large B-cell lymphoma (DLBCL) is rituximab plus C, H, vincristine, and P (R-CHOP), and it continues to evolve with pola-R-CHP showing higher complete response rates (CRR) of 78% and longer progression-free survival (PFS) than R-CHOP (Tilly 2022)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper